Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹21 Cr.
Stock P/E
-29
P/B
2.6
Current Price
₹24.6
Book Value
₹ 9.3
Face Value
10
52W High
₹26.6
52W Low
₹ 13.4
Dividend Yield
0%

Hamps Bio Overview

Business

Hamps Bio Ltd. operates primarily in the trading sector. Its core business model involves sourcing and distributing various goods, acting as an intermediary between producers/suppliers and end-users/retailers. The company generates revenue by purchasing goods at wholesale or negotiated prices and selling them at a margin, with profitability driven by volume, efficient supply chain management, and market price differentials. Without specific product details, it's understood to engage in general trading activities. The "Bio" in its name might suggest a focus on biological products, chemicals, pharmaceuticals, or agricultural commodities, but based on the "Trading" industry classification, it functions as a general merchant trader.

Revenue Mix

Given the classification as a generic "Trading" company, it is unlikely that detailed public segmentation or a diverse revenue mix is readily available without specific financial disclosures. Most of its revenue would likely come from the sale of traded goods. The company may engage in trading various categories of products, and its revenue mix would be dictated by the volume and margins achieved in each product category it trades.

Industry

The trading industry in India is highly fragmented, characterized by numerous small to medium-sized players, low barriers to entry, and intense competition. Companies often compete on price, supply chain efficiency, network, and credit terms. Hamps Bio Ltd., as a participant in this industry, likely occupies a position among many regional or national trading firms. Without specific market share or specialization details, its positioning would generally be undifferentiated, relying on its operational efficiency and relationships within its chosen product categories.

MOAT

For a general trading company, establishing a durable competitive advantage (moat) is challenging. There is typically no strong brand loyalty, significant switching costs for customers, or proprietary technology. While Hamps Bio Ltd. might develop operational efficiencies, strong supplier relationships, or an effective distribution network, these are generally replicable by competitors. Scale might offer some purchasing power, but a true moat in the trading sector is rare and often depends on highly specialized niches, proprietary information, or exclusive licenses, which are not apparent from the generic description.

Growth Drivers

Economic Growth: A growing Indian economy generally leads to increased demand for various goods, boosting trading volumes.

Expansion of Product Portfolio: Diversifying into new product categories or commodities that have strong demand or better margins.

Geographic Expansion: Extending its trading network to new regions within India or potentially internationally.

Supply Chain Optimization: Improving logistics and sourcing to enhance efficiency and reduce costs, thereby improving margins.

Market Volatility (Opportunistic): Profiting from price fluctuations in certain commodities if the company has the expertise and risk management to capitalize on them.

Risks

Market Price Volatility: Fluctuations in the purchase and sale prices of traded goods can significantly impact margins and profitability.

Inventory Risk: Holding inventory exposes the company to risks of obsolescence, damage, or decline in market value.

Credit Risk: Providing goods on credit to buyers can lead to bad debts if customers default on payments.

Intense Competition: The fragmented nature of the trading industry means constant pressure on margins and difficulty in retaining market share.

Regulatory Changes: Changes in trade policies, import/export duties, or taxation can affect the business model and profitability.

Supply Chain Disruptions: Issues with sourcing, logistics, or transportation can halt operations and impact revenue.

Management & Ownership

As an Indian listed company, Hamps Bio Ltd. likely has a promoter group holding a significant stake and guiding the company's long-term vision. Without specific information, it's difficult to comment on the individual management quality. In India, promoter-led companies often have a strong entrepreneurial drive, but corporate governance practices can vary. Ownership structure would typically involve the promoter group, institutional investors (if any), and public shareholders.

Outlook

Hamps Bio Ltd. operates in the highly competitive and fragmented trading sector. The bull case for the company would involve successfully leveraging India's robust economic growth, expanding its product offerings into high-demand or niche categories, and demonstrating superior supply chain management to achieve better margins and volumes. Effective risk management, particularly in managing price volatility and credit exposure, would be crucial for sustained growth. The bear case highlights the inherent challenges of the trading industry, including razor-thin margins, intense competition from numerous players, and susceptibility to market downturns and commodity price fluctuations. Without significant differentiation or proprietary advantages, growth may be primarily organic and tied closely to general economic conditions and the company's operational efficiency rather than structural industry advantages.

Hamps Bio Share Price

Live · BSE · Inception: 2007
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Hamps Bio Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Hamps Bio Profit & Loss

#(Fig in Cr.) Mar 2025 Mar 2026 TTM
Net Sales 7 8
Other Income 0 0
Total Income 7 9
Total Expenditure 6 8
Operating Profit 1 0
Interest 0 0
Depreciation 0 1
Exceptional Income / Expenses 0 0
Profit Before Tax 0 -1
Provision for Tax 0 0
Profit After Tax 0 -1
Adjustments 0 0
Profit After Adjustments 0 -1
Adjusted Earnings Per Share 0.3 -0.8

Hamps Bio Balance Sheet

#(Fig in Cr.) Mar 2025 Mar 2026
Shareholder's Funds 9 8
Minority's Interest 0 0
Borrowings 2 4
Other Non-Current Liabilities 0 0
Total Current Liabilities 2 4
Total Liabilities 13 16
Fixed Assets 2 9
Other Non-Current Assets 6 1
Total Current Assets 4 5
Total Assets 13 16

Hamps Bio Cash Flow

#(Fig in Cr.) Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 0 0
Cash Flow from Operating Activities -2 -1
Cash Flow from Investing Activities -6 -3
Cash Flow from Financing Activities 8 4
Net Cash Inflow / Outflow 0 0
Closing Cash & Cash Equivalent 0 0

Hamps Bio Ratios

# Mar 2025 Mar 2026
Earnings Per Share (Rs) 0.34 -0.85
CEPS(Rs) 0.77 0.09
DPS(Rs) 0 0
Book NAV/Share(Rs) 10.1 9.3
Core EBITDA Margin(%) 11.54 0.44
EBIT Margin(%) 8.15 -5.28
Pre Tax Margin(%) 6.06 -8.26
PAT Margin (%) 4.46 -8.72
Cash Profit Margin (%) 10.12 0.92
ROA(%) 2.34 -5.17
ROE(%) 3.38 -8.74
ROCE(%) 4.62 -3.35
Receivable days 65.25 59.81
Inventory Days 130.26 106.86
Payable days 114.67 57.11
PER(x) 62.55 0
Price/Book(x) 2.12 1.78
Dividend Yield(%) 0 0
EV/Net Sales(x) 3.22 2.49
EV/Core EBITDA(x) 23.35 57.24
Net Sales Growth(%) 0 27.08
EBIT Growth(%) 0 -182.39
PAT Growth(%) 0 -348.14
EPS Growth(%) 0 -348.14
Debt/Equity(x) 0.34 0.85
Current Ratio(x) 2.3 1.46
Quick Ratio(x) 1.03 0.75
Interest Cover(x) 3.89 -1.77
Total Debt/Mcap(x) 0.16 0.48

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +14% — — —
Operating Profit CAGR -100% — — —
PAT CAGR — — — —
Share Price CAGR +13% — — —
ROE Average -9% -3% -3% -3%
ROCE Average -3% +1% +1% +1%

Hamps Bio Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 71.99 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 28.01 %
# Mar 2025 Jun 2025 Sep 2025 Mar 2026
Promoter 71.9971.9971.9971.99
FII 0000
DII 0000
Public 28.0128.0128.0128.01
Others 0000
Total 100100100100

Hamps Bio Peer Comparison

Hamps Bio Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Hamps Bio Pros & Cons

Pros

  • Debtor days have improved from 114.67 to 57.11days.

Cons

  • Company has a low return on equity of -3% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp